Catherine Novack
Stock Analyst at JonesTrading
(4.61)
# 926
Out of 5,060 analysts
131
Total ratings
39%
Success rate
22.6%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Catherine Novack
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CAPR Capricor Therapeutics | Reiterated: Hold | n/a | $6.71 | - | 12 | Sep 27, 2026 | |
| DTIL Precision BioSciences | Reiterated: Buy | $30 | $5.77 | +419.93% | 4 | Aug 7, 2026 | |
| WVE Wave Life Sciences | Reiterated: Buy | $35 → $30 | $3.13 | +858.47% | 15 | Aug 7, 2026 | |
| DARE Daré Bioscience | Rated: Hold | n/a | $0.7246 | - | 7 | Jul 31, 2026 | |
| EQ Equillium | Rated: Hold | n/a | $1.19 | - | 5 | Jul 31, 2026 | |
| FEMY Femasys | Rated: Hold | n/a | $1.67 | - | 9 | Jul 31, 2026 | |
| PRQR ProQR Therapeutics | Reiterated: Buy | $11 → $10 | $1.31 | +663.36% | 4 | Jun 26, 2026 | |
| SPRB Spruce Biosciences | Initiated Coverage: Buy | $135 | $39.65 | +240.48% | 1 | Jun 8, 2026 | |
| RZLT Rezolute | Reiterated: Buy | $6 | $3.58 | +67.60% | 9 | Jun 2, 2026 | |
| IBIO iBio, Inc. | Reiterated: Buy | $7 | $0.7663 | +813.48% | 2 | May 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | $23 | $8.49 | +170.91% | 3 | May 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $16.28 | - | 10 | Apr 10, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $0.45 | - | 4 | Apr 10, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $7 → $13 | $2.00 | +550.00% | 9 | Feb 24, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $143 → $209 | $120.30 | +73.73% | 7 | Feb 24, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $43 | $36.35 | +18.29% | 1 | Dec 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $33 | $3.80 | n/a | 1 | Sep 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $6 → $9 | $0.7001 | n/a | 14 | Aug 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $30 | $14.25 | n/a | 1 | Jun 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $15 | $1.04 | n/a | 5 | Nov 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $160 → $60 | $1.14 | n/a | 4 | Jun 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $6.08 | n/a | 4 | Nov 15, 2021 |
Capricor Therapeutics
Sep 27, 2026
Reiterated: Hold
Price Target: n/a
Current: $6.71
Upside: -
Precision BioSciences
Aug 7, 2026
Reiterated: Buy
Price Target: $30
Current: $5.77
Upside: +419.93%
Wave Life Sciences
Aug 7, 2026
Reiterated: Buy
Price Target: $35 → $30
Current: $3.13
Upside: +858.47%
Daré Bioscience
Jul 31, 2026
Rated: Hold
Price Target: n/a
Current: $0.7246
Upside: -
Equillium
Jul 31, 2026
Rated: Hold
Price Target: n/a
Current: $1.19
Upside: -
Femasys
Jul 31, 2026
Rated: Hold
Price Target: n/a
Current: $1.67
Upside: -
ProQR Therapeutics
Jun 26, 2026
Reiterated: Buy
Price Target: $11 → $10
Current: $1.31
Upside: +663.36%
Spruce Biosciences
Jun 8, 2026
Initiated Coverage: Buy
Price Target: $135
Current: $39.65
Upside: +240.48%
Rezolute
Jun 2, 2026
Reiterated: Buy
Price Target: $6
Current: $3.58
Upside: +67.60%
iBio, Inc.
May 13, 2026
Reiterated: Buy
Price Target: $7
Current: $0.7663
Upside: +813.48%
May 8, 2026
Upgraded: Buy
Price Target: $23
Current: $8.49
Upside: +170.91%
Apr 10, 2026
Rated: Hold
Price Target: n/a
Current: $16.28
Upside: -
Apr 10, 2026
Rated: Hold
Price Target: n/a
Current: $0.45
Upside: -
Feb 24, 2026
Reiterated: Buy
Price Target: $7 → $13
Current: $2.00
Upside: +550.00%
Feb 24, 2026
Reiterated: Buy
Price Target: $143 → $209
Current: $120.30
Upside: +73.73%
Dec 23, 2025
Initiated Coverage: Buy
Price Target: $43
Current: $36.35
Upside: +18.29%
Sep 30, 2025
Initiated Coverage: Buy
Price Target: $33
Current: $3.80
Upside: n/a
Aug 8, 2025
Reiterated: Buy
Price Target: $6 → $9
Current: $0.7001
Upside: n/a
Jun 25, 2025
Initiated Coverage: Buy
Price Target: $30
Current: $14.25
Upside: n/a
Nov 15, 2024
Reiterated: Buy
Price Target: $15
Current: $1.04
Upside: n/a
Jun 3, 2024
Reiterated: Buy
Price Target: $160 → $60
Current: $1.14
Upside: n/a
Nov 15, 2021
Downgraded: Hold
Price Target: n/a
Current: $6.08
Upside: n/a